Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
about
Mutator pathways unleashed by epigenetic silencing in human cancerThe pathology of familial breast cancer: Immunohistochemistry and molecular analysisDo we now have a relevant animal model for breast cancer?Killing the umpire: cooperative defects in mitotic checkpoint and BRCA2 genes on the road to transformationRole of BRCA gene dysfunction in breast and ovarian cancer predisposition.Are Trp53 rescue of Brca1 embryonic lethality and Trp53/Brca1 breast cancer association related?The p53 pathway in breast cancerFunctional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversityMapping the physical and functional interactions between the tumor suppressors p53 and BRCA2.p53-mediated DNA repair responses to UV radiation: studies of mouse cells lacking p53, p21, and/or gadd45 genes.Differential transactivation by the p53 transcription factor is highly dependent on p53 level and promoter target sequence.Assessing TP53 status in human tumours to evaluate clinical outcome.High frequency of complex TP53 mutations in CNS metastases from breast cancer.Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.The tumor suppressor gene TP53: implications for cancer management and therapy.Breast cancer susceptibility and the DNA damage response.The role of p53 mutations as a prognostic factor and therapeutic target in inflammatory breast cancer.Mouse models of BRCA1 and BRCA2 deficiency: past lessons, current understanding and future prospects.BRCA1 and BRCA2: different roles in a common pathway of genome protection.Mutant p53 in cancer: new functions and therapeutic opportunities.BRCA1 signals ARF-dependent stabilization and coactivation of p53.Two identical triplet sisters carrying a germline BRCA1 gene mutation acquire very similar breast cancer somatic mutations at multiple other sites throughout the genome.N-Methyl-N-nitrosourea as a mammary carcinogenic agent.BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targetsA novel p53 mutational hotspot in skin tumors from UV-irradiated Xpc mutant mice alters transactivation functions.p73 transcriptional activity increases upon cooperation between its spliced forms.p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay.Dualistic Role of BARD1 in Cancer.Genomic analysis of inherited breast cancer among Palestinian women: Genetic heterogeneity and a founder mutation in TP53.Recurrent TP53 missense mutation in cancer patients of Arab descent.Effects of oncogenic mutations and DNA response elements on the binding of p53 to p53-binding protein 2 (53BP2).Tumour p53 mutations exhibit promoter selective dominance over wild type p53.Spontaneous and irradiation-induced tumor susceptibility in BRCA2 germline mutant mice and cooperative effects with a p53 germline mutation.
P2860
Q22242850-C716F2AD-7583-4AE1-8931-4873DEBA3A0DQ24800411-B6C1C3C9-CC96-482E-8BD5-8C481B0A0436Q24800439-0BB77DB2-EDBD-4E40-A138-CDBB30230294Q24800509-D7872CF2-C57C-49DA-BD19-1994F6DAD7C4Q24800677-937EA191-DE66-4066-B31D-F3DC72316230Q24802238-7F40301D-3B89-4C9A-9B13-7ED2559F4AE4Q24802349-48C2389A-F16C-45D0-AEE3-C0AE1CA551C1Q30479523-E075E574-9631-47FC-A15E-C8746983B27AQ33928616-278AD87A-A2AD-4150-9579-C5BA881D7DB3Q33963455-08098374-3107-4C7B-A30E-8619507143D0Q34443272-54CF1C49-2970-4A2B-B157-3F35A88B9CBDQ34570100-28912A6D-847D-4D62-AC8A-88F0C2DA4606Q35682017-7ED7B20C-0220-4E00-BFE3-ED65AF6B16FEQ35858051-D823BF8A-97C2-4F4E-94A1-55B2ABBA05FEQ35986418-9E0DADEC-D97A-478E-B0A4-51C36CF41D23Q36108626-B3B741D6-87BF-4902-8288-87F26D75AD5FQ36430748-6DB0364C-E36C-447D-967A-112B9C03ADF0Q36602578-C4AB1096-9C2D-44D7-851A-554719A513BEQ37149848-9FA0C9A8-12B8-4438-9BB7-69BD19DD1C20Q38197826-A19FCE8B-2DAD-4D7E-8B15-375F476C009AQ38317581-748B1543-5AD7-478A-8C35-DFE5EA7F1C44Q38464687-EDF99715-C3C6-4D13-84A9-227F306BB2FDQ38589651-EFE8943D-5E51-4446-B06A-8F4820CBA93FQ39674825-9DC589F0-D625-4B57-8BA3-C03A362F67D3Q40711394-82545AC8-C781-4866-B932-37BC9E26A0E9Q40896738-AC898C4D-FDE0-4612-A0C7-AB1A346436D8Q45876572-64430CD8-DF9E-40DB-A292-F4739E2131AEQ47177315-89A577DD-A649-4DDC-8D22-F0A5B7CEA849Q47769154-EBBC7E17-A7F9-4785-9E51-DC12056BBB88Q51057181-B60D17F3-C396-4323-A69E-CD49BC618F7CQ51151705-7572B4F8-2752-4370-9928-FA2EC7762A72Q53391608-7F10F822-DCB5-448A-81DA-8A292E49BB1AQ53601631-689E40D4-1E88-4C2F-B9C7-D6B308D9BA8B
P2860
Novel p53 mutants selected in BRCA-associated tumours which dissociate transformation suppression from other wild-type p53 functions.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Novel p53 mutants selected in ...... other wild-type p53 functions.
@en
Novel p53 mutants selected in ...... other wild-type p53 functions.
@nl
type
label
Novel p53 mutants selected in ...... other wild-type p53 functions.
@en
Novel p53 mutants selected in ...... other wild-type p53 functions.
@nl
prefLabel
Novel p53 mutants selected in ...... other wild-type p53 functions.
@en
Novel p53 mutants selected in ...... other wild-type p53 functions.
@nl
P2093
P2860
P356
P1433
P1476
Novel p53 mutants selected in ...... other wild-type p53 functions.
@en
P2093
Crompton MR
Crossland S
Gusterson BA
P2860
P2888
P304
P356
10.1038/SJ.ONC.1202565
P407
P577
1999-04-01T00:00:00Z